KaliVir Immunotherapeutics
Develops oncolytic immunotherapies for patients with advanced solid tumors
$14MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops oncolytic immunotherapies for patients with advanced solid tumors